Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 88, Issue 3, 2004, Pages 265-275

  Liu, Zhi Jian ^a   Zhu, Bao Ting ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

17 estradiol; 2 MeO E2; 2 methoxyestradiol; catechol O methyltransferase; COMT; E2; Eagle's modified minimum essential medium; EMEM; ER; estrogen receptor; HPLC; IMEM; Iscove's modified minimum essential medium

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ESTROGEN ACTIVITY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; MITOGENESIS; RECEPTOR AFFINITY;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; MITOGENS; RECEPTORS, ESTROGEN;

CICONIIFORMES; MINK CELL FOCUS-FORMING VIRUS;

EID: 2142761525     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2003.12.003     Document Type: Article

References (38)

1. Zhu B.T., Conney A.H. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res. 58:1998;2269-2277
2. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 19:1998;1-27
3. Korenman S.G. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids. 13:1969;163-177
4. Jellinck P.H., Newcombe A.M. Effect of catechol estrogens and estradiol on the induction of uterine peroxidase. J. Steroid Biochem. 13:1980;681-683
5. Merriam G.R., MacLusky N.J., Picard M.K., Naftolin F. Comparative properties of the catechol estrogens. I. Methylation by catechol-O- methyltransferase and binding to cytosol estrogen receptors. Steroid. 36:1980;1-11
6. Pribluda V.S., Gubish E.R., Lavallee T.M., Treston A., Swartz G.M., Green S.J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 19:2000;173-179
7. Seegers J.C., Aveling M.L., van Aswegen C.H., Cross M., Kock F., Joubert W.S. The cytotoxic effects of estradiol-17β catecholestradiols and methoxyestradiols on dividing MCF-7 and Hela cells. J. Steroid Biochem. 32:1989;797-809
8. Lottering M.-L., Haag M., Seegers J.C. Effects of 17β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res. 52:1992;5926-5932
9. Fotsis T., Zhang Y., Pepper M.S., Aldercreutz H., Montesano R., Nawroth P.P., et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature. 368:1994;237-239
10. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57:1997;81-86
11. Cushman M., He H.M., Katzenellenbogen J.A., Varma R.K., Hamel E., Lin C.M., et al. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem. 40:1997;2323-2334
12. Cushman M., He H.M., Katzenellenbogan J.A., Lin C.M., Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J. Med. Chem. 38:1995;2041-2049
13. Qadan L.R., Perez-Stable C.M., Anderson C., D'Ippolito G., Herron A., Howard G.A., et al. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem. Biophys. Res. Commun. 285:2001;1259-1266
14. Kumar A.P., Garcia G.E., Slaga T.J. 2-Methoxyestradiol blocks cell-cycle progression at G2/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinog. 31:2001;111-124
15. Lin H.L., Liu T.Y., Wu C.W., Chi C.W. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G2/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer. 92:2001;500-509
16. Schumacher G., Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J. Cancer Res. Clin. Oncol. 127:2001;405-410
17. Hughes R.A., Harris T., Altmann E., McAllister D., Vlahos R., Robertson A., et al. 2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding. Mol. Pharmacol. 61:2002;1053-1069
18. Qanungo S., Basu A., Das M., Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene. 21:2002;4149-4157
19. LaVallee T.M., Zhan X.H., Herbstritt C.J., Kough E.C., Green S.J., Pribluda V.S. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 62:2002;3691-3697
20. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80:1995;2918-2925
21. Gillies R.J., Diclier N., Denton M. Determination of cell number in monolayer culture. Anal. Biochem. 159:1986;109-113
22. Zager R.A. Calcitriol directly sensitizes renal tubular cells to ATP-depletion and iron-mediated attack. Am. J. Pathol. 154:1999;1899-1910
23. Holst-Hansen C, Brunner N. MTT-cell proliferation assay. In: Cell biology: a laboratory handbook, vol. 1. 2nd ed. 1998. p. 16-8.
24. Jordan V.C., Murphy C.S. Endocrine pharmacology of antiestrogens as anti-tumor agents. Endocr. Rev. 11:1990;578-611
25. Pratt S.E., Pollak M.N. Estrogen and antiestrogen modulation of MCF-7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res. 53:1993;5193-5198
26. van der Berg B., Rutteman M., de Laat S.W., van Zoelen E.J.J. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J. Cell. Physiol. 134:1988;101-108
27. Chappell J., Leitner J.W., Solomon S., Golovchennko I., Goalstone M.L., Draznin B. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. J. Biol. Chem. 276:2001;38023-38028
28. WAF1/Cip1. J. Biol. Chem. 276:2001;25823-25833
29. Zhu B.T., Evaristus E.N., Antoniak S.K., Sarabia S.F., Ricci M.J., Liehr J.G. Metabolic deglucuronidation and demethylation of estrogen conjugates as a source of parent estrogens and catecholestrogen metabolites in Syrian hamster kidney, a target organ of estrogen-induced tumorigenesis. Toxicol. Appl. Pharmacol. 136:1996;186-193
30. Jeng M.H., Jiang S.Y., Jordan V.C. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett. 82:1994;123-128
31. Wang W., Smith R., Burghardt R., Safe S.H. 17β-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. Mol. Cell. Endocrinol. 133:1997;49-62
32. Lee Y., Renaud R.A., Friedrich T.C., Gorski J. Estrogen causes cell death of estrogen receptor stably transfected cells via apoptosis. J. Steroid Biochem. Mol. Biol. 67:1998;327-332
33. O'Regan R.M., Jordan V.C. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol. 3:2002;207-214
34. O'Regan R.M., Jordan V.C. Tamoxifen to raloxifene and beyond. Semin. Oncol. 28:2001;260-273
35. Bentrem D.J., Jordan V.C. Role of antiestrogens and aromatase inhibitors in breast cancer treatment. Curr. Opin. Obstet. Gynecol. 14:2002;5-12
36. Assikis V.J., Buzdar A. Recent advances in aromatase inhibitor therapy for breast cancer. Semin. Oncol. 29(3 Suppl 11):2002;120-128
37. Bundred N., Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert. Rev. Anticancer Ther. 2:2002;151-160
38. Goss P.E., Smith R.E. Letrozole for the management of breast cancer. Expert. Rev. Anticancer Ther. 2:2002;249-260